The SNAI1’s Protein Mystery Revelation

Oncotarget is a journal covering researches involving oncology, a branch of science which deals with all aspects of cancer from its treatment to prevention, and cure. Oncotarget conducts analyses on every scientific archive to make reliable results rapidly to be accessed by other medical specialists. The bio-medical journal avails its publications to the people through the PubMed Central, PubMed, Embase, BIOSIS, and Scopus. From the 19th of September 2017, the journal intends to publish two publications each week on Tuesday and Friday to avail oncologists the latest researches on cancer.

On a recent publication from Oncotarget on the 20th of November 2017, the journal published the new research as to how cancer cells move to all parts of the body. Cells from the initial tumor become metastatic and spread from that part of the body to another leading to formation of a secondary tumor. The process that allows the cells to move is the epithelial-to-mesenchymal transition (EMT) process. EMT process is activated by the proteins called transforming growth factor β (TGFβ). The protein also activates the SNAI1 protein which is also responsible for the EMT process. Learn more about Oncotarget at Research Gate.

Researchers are currently focusing on the EMT process which causes cancer cells to become metastatic which will inhibit the spread of cancer cells to other parts of the body. Oncotarget released research conducted by the Uppsala and Umea University which can help in altering of the SNAI1 protein. The process involves altering one amino-acid making up the protein. The process is also referred to as sumoylation. The amino-acid making the Snaill protein alteration causes the protein itself to have a remodeled structure as well as the metastatic and invasive properties of cancer cells.

Read more:

The research teams also discovered that the SNAI1 protein was responsible for expressing oncogenes thus the best method to inhibit the expression is by affecting the very SNAI1 protein. So far, the team has made the research to inhibit prostate cancer cells and is now focusing on breast cancer tumors. The plan for the future is to be able to inhibit the expression of different cancer cells within major organs of the body and to be able to stop cancer disease in the body. Watch this video on Youtube.

Oncotarget Maximizes the Impact of Medical Research

Oncology is the study and treatment of tumors, but also includes the prevention, diagnosis, and treatment of cancer. This area of study is filled with experts who have specialties in this field and are dedicated to the study of oncology. Research in the biomedical sciences can be competitive as researchers strive to gain sponsorship and credit for the work they’ve done. Oncotarget provides an excellent go-between for people in this field since they can still expand the effects of their research through an open access peer reviewed journal.Oncotarget has the goal of a life without disease and was first established in 2010 and published by Impact Journals. This medical journal is open access, meaning anyone can have access to the peer reviewed papers published weekly. The concept behind Oncotarget is to have a greater impact on research and to bring down the walls between specialties.

When it comes to the world of oncology, specialties are often separated and rarely communicate with each other. This can make spreading information between them nearly impossible, especially when there is a sense of competition among researchers. Oncotarget provides the right platform for researchers to be able to come in and have access to information they may not have known otherwise. This brings down the walls between specialties and helps to lead to exceptional discoveries in the world of oncology.Oncotarget is focused on maximizing the impact of the research done by professionals in the medical and biomedical sciences.

They understand the kind of impact an exceptional discovery can be made in the medical community and how vital it is to have access to the information. The online medical journal publishes papers weekly online and each issue or paper can also be printed on special demand.Scientific results can become more readily available to professionals and maximize the results for these discoveries. Eliminating the borders between specialties is the first step towards fostering applications between clinical and basic science to help combat disease. The success of the medical journal has even prompted Oncotarget to begin accepting other peer reviewed papers published in the medical sciences.

The Outstanding EricLefkofsky

The Outstanding Eric Lefkofsky

Born on September 2, 1969 in Detroit, Michigan, Eric Lefkofsky is co-founder and CEO of Tempus, co-founder of Groupon, Echo Global Logistics, InnerWorkings, Mediaocean and Uptake. He supports several charities by creating, buying and selling companies then giving a portion of that money back to the communities such as health, education, human rights, arts and culture. He graduated from University of Michigan and went to law school where he sold carpets to make money during his freshman year. His views on how to make people`s lives easier has come to life in these amazing companies. Lately, his startup to cure cancer has influenced many to join his vision.


One of his widely-known areas of expertise is his co-foundation of Tempus. Tempus is a health-technology company dedicated to providing cancer care. The company`s motto is to improve positive outcomes for their patients. CEO Lefkofsky`s investments provide successful continuance of genomic sequencing data so that every patient`s tumor is deliberately evaluated. Tempus provides physicians a robotic technological lab to optimize sequencing for an unlimited number of patients. This laboratory provides fast results of patient RNA sequencing within two to three weeks of receiving patients` samples. Many providers such as Dr. David Agus as chairman of The Scientific Advisory Board, University of Michigan collaborates in pancreatic cancer research, the Mayo Clinic, Dr. Gary Palmer as Chief Medical Officer of Tempus, and essentially the University Hospitals: Seidman Cancer Center wholeheartedly believe in this startup and strive to achieve patient satisfaction.

Accelerated Disruption

Business Deals.Altruistic ideas.Investments. These are the main parts of Accelerated Disruption in which Lefkofsky has subserviently invested $1,000,000 into. This disrupted into Groupon and Groupon is currently accelerating into a business deal with Google. Per Lefkofsky, accelerated disruption must be succeeded by 18 laws (in which he wrote a book for those interested in becoming an entrepreneur) to deliver creative businesses one after another and turn them into startup ventures. As disruption increases, acceleration of profits, business relationships, and quick release products improve immensely-there is no doubt that Eric Lefkofsky`s empire will continue to prosper.